Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis
Top Cited Papers
- 1 March 2006
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 64 (3) , 784-791
- https://doi.org/10.1016/j.ijrobp.2005.06.023
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Measuring inconsistency in meta-analysesBMJ, 2003
- Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancerSeminars in Oncology, 2002
- A phase III randomized evaluation of amifostine in stage IIIA/IIIB non[ndash ]small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findingsSeminars in Oncology, 2002
- Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: Subcutaneous amifostine and computed tomography-based target delineationSeminars in Oncology, 2002
- Radioprotective effect of amifostine in patients with head and neck squamous cell carcinomaSeminars in Oncology, 2002
- Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapySeminars in Oncology, 2002
- Cisplatin, radiation, and amifostine in carcinoma of the uterine cervixInternational Journal of Gynecologic Cancer, 1999
- Use of radiation with or without WR-2721 in advanced rectal cancerCancer, 1992
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986